Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  NATIONAL STOCK EXCHANGE OF INDIA  >  Glenmark Pharmaceuticals Ltd    GLENMARK   INE935A01035

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Glenmark Pharmaceuticals : launches ‘Apremilast’ an advanced oral systemic treatment for Psoriasis

share with twitter share with LinkedIn share with facebook
share via e-mail
0
11/10/2017 | 07:58pm CET

Apremilast is a phosphodiesterase 4 (PDE4) inhibitor which is indicated for the treatment of moderate to severe Psoriasis. The launch of Apremilast will revolutionize the treatment of Psoriasis impacting close to 33 million Indians suffering from the condition. Glenmark Pharmaceuticals Limited announced the launch of Apremilast in India. Apremilast is the first advanced Oral Systemic treatment for Psoriasis in India. Apremilast is a phosphodiesterase 4 (PDE4) inhibitor which is indicated for the treatment of moderate to severe Psoriasis. The launch of Apremilast will revolutionize the treatment of Psoriasis impacting close to 33 million Indians suffering from the condition.

Glenmark Pharmaceuticals Ltd is currently trading at Rs 589.35, down by Rs 3.3 or 0.56% from its previous closing of Rs 592.65 on the BSE.

The scrip opened at Rs 592 and has touched a high and low of Rs 594.55 and Rs 586.65 respectively. So far 165511(NSE+BSE) shares were traded on the counter. The current market cap of the company is Rs 16724.2 crore.

Apremilast is an advanced oral treatment for Psoriasis which addresses the limitations of the current available therapies in India. It acts in a targeted manner at an early stage of the disease progression. Also, it is an immunomodulator whereas the other available drugs in the country are immunosuppressant including biologics and are mostly indicated for the treatment of oncological conditions. Immunosuppressants suppress the immune system thereby making the body susceptible to various infections. Apremilast being an immunomodulator does not suppress the immune system and treats the condition of psoriasis at an intracellular level which will benefit psoriasis patients across the country.

Apremilast is an oral therapy which can be self-administered unlike some of the currently available injectable therapy which have to be administered by paramedics. Further, Apremilast is a safer drug having no effects on other organs like the liver and kidney and does not require routine laboratory diagnostic tests like CBC, liver & Kidney test or TB screening as required in the case of other therapies used currently.

Glenmark has launched Apremilast under the brand name ‘Aprezo’indicated for the treatment of Psoriasis. Glenmark received approval from DCGI for Apremilast after conducting clinical trials on the molecule as per the regulatory requirements.

Sujesh Vasudevan, President and Head – India, Middle East and Africa, “Glenmark is proud to be the first player to introduce Apremilast, an advanced oral and safe treatment for Psoriasis, in India. Glenmark has been in the field of Dermatology for 4 decades bringing advanced therapies to Indian patients. With the launch of Apremilast, we are aiming to transform the treatment paradigm for millions of Psoriasis patients in the country.”

Rajesh Kapur, Senior Vice President – Sales & Marketing, Glenmark Pharmaceuticals, said,“Apremilast is a safer and efficacious treatment compared to the existing treatment available in the country. Apremilast is the only oral medicine available in the country exclusively for Psoriasis. In addition to this, it also addresses the several limitations of existing treatments like routine laboratory monitoring. We hope that millions of patients in India will now be able to live a better quality of life with this revolutionary treatment.”

Globally, about 3% of the world population has some form of Psoriasis. Another study reveals that the prevalence of psoriasis in countries ranges between 0.09% and 11.43%, making psoriasis as one of the serious issues.

India has now become one of the largest patient pool in the world and is estimated to have around 33 million psoriasis patients. As per a study on psoriasis in India, based on data collected across various medical colleges located in Lucknow, Dibrugarh, Calcutta, Patna, Darbhanga, New Delhi and Amritsar, it was found that the incidence of psoriasis among total skin patients ranged between 0.44 and 2.2%. It was also found that the ratio of male to female (2.46:1) was very high and the highest incidence was noted in the age group of 20-39 years.

Apremilast will revolutionize the treatment for 33 million psoriasis patients in the country. Apremilast is the first oral treatment in India specific for psoriasis treatment; it is convenient to administer, it is safer compared to existing therapies and will transform the psoriasis treatment regime in the country.

(c) 2017India Infoline Ltd. All rights Reserved. Provided by SyndiGate Media Inc. (Syndigate.info)., source Middle East & North African Newspapers

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on GLENMARK PHARMACEUTICALS L
11/17 GLENMARK PHARMACEUTICALS : launches nicotine gum Kwitz
11/16 GLENMARK PHARMACEUTICALS : launches nicotine replacement therapy in India
11/10 GLENMARK PHARMACEUTICALS : launches ‘Apremilast’ an advanced oral sy..
11/10 GLENMARK PHARMACEUTICALS : Aims to Transform the Treatment for Psoriasis in Indi..
11/02 Four pharma firms face us price-fixing charge
10/25 GLENMARK PHARMACEUTICALS : launches oral drug for Psoriasis treatment in India
10/17 GLENMARK PHARMACEUTICALS : `s Glenn Saldanha takes over as president of pharma l..
10/17 GLENMARK PHARMACEUTICALS : Glenn saldanha appointed ipa president
10/17 GLENMARK PHARMACEUTICALS : Drug gets usfda nod
09/25 GENERICS TO DRIVE GROWTH OVER NEXT T : Glenmark
More news
Financials ( INR)
Sales 2018 95 326 M
EBIT 2018 16 070 M
Net income 2018 10 807 M
Debt 2018 34 514 M
Yield 2018 0,44%
P/E ratio 2018 14,89
P/E ratio 2019 13,04
EV / Sales 2018 2,09x
EV / Sales 2019 1,85x
Capitalization 164 B
Chart GLENMARK PHARMACEUTICALS L
Duration : Period :
Glenmark Pharmaceuticals L Technical Analysis Chart | GLENMARK | INE935A01035 | 4-Traders
Technical analysis trends GLENMARK PHARMACEUTICALS L
Short TermMid-TermLong Term
TrendsBearishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 32
Average target price 775  INR
Spread / Average Target 33%
EPS Revisions
Managers
NameTitle
Glenn Mario Saldanha Chairman, Chief Executive Officer & MD
Fred Grossman Co-President & Chief Medical Officer
Kanish Malik Co-President & Head-Global Operations
Kurt Stoeckli Co-President & Chief Scientific Officer
P. Ganesh Co-President & Chief Finance Officer